Advanced lung cancer
Conditions
Interventions
Experimental group:Camrelizumab single agent/combined with others
Sponsors
Harbin Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Patients with advanced lung cancer diagnosed by pathology or clinical diagnosis; 2.Patients who have measurabled tumor lesions (spiral CT scan >= 10mm, meet RECIST 1.1 standard); 3.Expected survival period > 3 months; 4.Age: >= 18 years old, regardless of gender; 5.ECOG PS: 0-2 points; 6.The functions of vital organs meet the following requirements: a. The absolute count of neutrophils >= 1.5 x 10^9/L, platelets >= 100 x 10^9/L, hemoglobin >= 9g/dL; b. Bilirubin 35g/ml, prothrombin time extension 60 mL/min; 7.Women of childbearing age must have a negative pregnancy test (ßHCG) before starting treatment. Women and men of childbearing age (have sex with women of childbearing age) must agree to use effective contraception during treatment and 6 months after the last therapeutic dose; 8.Patients voluntarily joined the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who have suffered from other malignant tumors in the past or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 2.Active tuberculosis infection. After intensive anti-tuberculosis treatment, the investigator will determine whether it is appropriate to participate in this trial; 3.Patients with active, known or suspected autoimmune diseases, hypothyroidism requiring only hormone replacement therapy, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or hair loss) can be selected; 4.Congestive heart failure, uncontrollable arrhythmia, myocardial infarction within 6 months, unstable angina, stroke or transient ischemic attack; 5.Patients receiving hematopoietic stem cell or organ transplantation; 6.Live vaccines have been vaccinated or will be vaccinated within 30 days before the administration of Camrelizumab; 7.Pregnant or lactating women; 8.Patients who cannot comply with the trial protocol or cannot cooperate with follow-up; 9.Patients who have a history of psychotropic drug abuse, alcohol or drug abuse; 10.The researcher thinks it is inappropriate to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;DCR;OS; | — |
Countries
China
Contacts
Public ContactShuyan Liu
Harbin Chest Hospital
Outcome results
None listed